Minerva Capital Research Solutions

Sai Parenterals Ltd

NSE: SAIPARENTBSE: 544742
₹ 494.00▼ 7.75 (−1.54%)19 Nov, 03:29 pm IST
Market cap
₹ 2,204 Cr.
P/E
88.9x
P/B
4.52x
52-week range
400 – 706
ROE
5%
ROCE
5%
Dividend yield
0%
Debt / equity
0.96
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 222 companies →

Sai Parenterals Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)88.9 against a typical 32.9: pricier than most peers (1st = cheapest).188th of 220
  • Sales growth+103.1% against a typical +17.4% from a year earlier.18th of 199
  • Share price, 3 months−9.1% against a typical −1.4%.152nd of 211
  • Size₹ 2,204.1 Cr. market value against a typical ₹ 488.8 Cr. (1st = largest).71st of 205

Latest announcements

Exchange filings and their impact on the company.

  • 16 Nov 2026Outcome without intimationMedium impactPositivePrice −2% on 17 Nov
    Sai to buy majority of Bion Therapeutics with ~Rs 57 cr annualized sales for cash by end-November via subsidiary.

    Sai Parenterals board on 16 Nov 2026 approved signing an agreement through its wholly owned subsidiary SP Analytics to acquire a majority stake in Hyderabad-based Bion Therapeutics India, a branded formulations business. Bion reported turnover of Rs 28.22 cr for H1 to Sep 2026 and total income of Rs 47.29 cr in FY26. The all-cash deal is expected to close by 30 Nov 2026 and will be funded from IPO proceeds earmarked for general corporate purposes plus debt, making Bion a step-down subsidiary.

    Filing
  • 7 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesHigh impactVery positivePrice +3.6% on 8 Nov
    H1 ahead of Rs 750 cr plan with Q2 margin at 21% and Rs 1506 cr contracted Australia book underpins strong next 12 months as new capacities ramp.

    Sai Parenterals reported Q2 FY27 revenue of Rs 196 cr, up 9% sequentially, with gross margin improving to 47.5% and EBITDA margin to 21.1%, taking H1 revenue to Rs 376 cr against a Rs 750 cr full-year target. Management said it will comfortably cross the target and sustain gross margin above 45% and EBITDA above 17%. It also renewed two Australia OTC contracts totalling AUD232m or about Rs 1506 cr, is expanding Unit III capacity by 81% from December 2026, and will commission the Adelaide plant in January 2027 and a new Rs 215 cr injectable facility in July 2027.

    Filing
  • 1 Nov 2026Outcome of Board MeetingHigh impactVery positivePrice −7.9% on 2 Nov
    H1 revenue and profit already beat FY26 full year, pointing to ~2x sales and earnings run-rate.

    Sai Parenterals reported Q2 FY27 consolidated revenue of Rs 194 crore versus Rs 53.5 crore a year ago and PAT of Rs 10.5 crore versus Rs 6.35 crore, taking H1 revenue to Rs 373.6 crore and PAT to Rs 18.4 crore, already above FY26 full-year profit. Operating cash flow was sharply negative at minus Rs 205 crore in H1 as receivables surged and cash fell to Rs 129 crore, while CWIP stood at Rs 269 crore. The board also completed the 60% acquisition of Saicriti Pharma making it a subsidiary and approved buying the balance 25% of SP Analytics for Rs 25,000 to make it wholly owned.

    Filing

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Moderate safety, with caution

Rated BBB- by Acuite
BBB-
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
AcuiteACUITE BBB-Stable19 Nov 2026
Credit rating actions
RatingDetails
19 Nov 2026
▲ Upgrade
ACUITE BBB-MediumAcuite₹ 9 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
1 Nov 2026Financial ResultsTo consider and approve the financial results for the period ended September 30, 2026
30 Sep 2026General—
11 Aug 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
23 May 2026Financial ResultsTo consider and approve the financial results for the period ended December 31, 2025
20 Apr 2026Other business mattersTo consider other business matters

Share price

1M change +2.28%
1 of 3 filing days came with a big price moveBiggest −7.9% on 2 Nov 2026AI reading matched the move 0 of 1
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Jun 2025Dec 2025Mar 2026Jun 2026Sep 2025Sep 2026
Sales339619817954195
Expenses2910017215542155
Operating Profit5−426241140
OPM %14%−3.7%13%13%21%21%
Other Income133414
Interest258929
Depreciation1688125
Profit before tax2−121210910
Tax %30%−43%−6%19%31%−6%
Net Profit1−7138611
EPS in Rs0.52−1.82.981.791.722.38
YoY Sales growth———435—264

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
—
5 Years
—
3 Years
58%
TTM
134%
Compounded Profit Growth
10 Years
—
5 Years
—
3 Years
48%
TTM
−1%
Stock Price CAGR
10 Years
—
5 Years
—
3 Years
—
TTM
—
Return on Equity
10 Years
—
5 Years
—
3 Years
9%
TTM
—

Shareholding

Latest: Sep 2026.

Promoters
51.16%
FIIs
2.85%
DIIs
7.83%
Public
38.16%

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 88.9xEPS (12 months) ₹ 5.35Median P/E 145x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Sai Parenterals Ltd₹ 494.00₹ 2,204 Cr.88.9x4.5x5%—
Sun Pharmaceutical Industries₹ 1,880.00₹ 4,51,064 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 11,442.00₹ 3,03,749 Cr.73x11.4x16.2%24.3%
Torrent Pharmaceuticals₹ 4,662.15₹ 1,77,327 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,391.80₹ 1,12,438 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,189.90₹ 1,18,693 Cr.21.2x4.2x19.7%18.5%

Management

Anil Kumar Karusala
Executive Chairman, Managing Director
D.B.Venkoji Prakash
Chief Executive Officer
Anil Kumar
Chief Financial Officer
Shivali Aggarwal
Company Secretary, Compliance Officer
Vijitha Gorrepati
Whole Time Director

Prices are delayed and for information only. Nothing on this page is investment advice.